Novartis gets US approval for $2.1 million gene therapy

Swiss pharmaceutical company, Novartis, announced that it has received US regulatory approval for a gene therapy that treats a rare childhood disorder and has a price tag of $2.1 million, making it the most expensive drug in history. The company said Zolgensma was a one-time treatment for spinal muscular atrophy and will cost $2.125 million payable over five years.